Source comparison
CJC-1295 no DAC & Ipamorelin vs Ipamorelin: Full Comparison
Before deciding between monotherapy and combination protocols, researchers must weigh receptor mechanisms, dosing logistics, GH secretion dynamics, and study-specific endpoints. The table below distils the key differences. Receptor Pathway Dual GHRH/GHRP agoni
This comparison does not assign a generated winner or score.
- Before deciding between monotherapy and combination protocols, researchers must weigh receptor mechanisms, dosing logistics, GH secretion dynamics, and study-specific endpoints. The table below distils the key differences.
- Receptor Pathway
- Dual GHRH/GHRP agonism. CJC-1295 primes somatotrophs, Ipamorelin triggers release
- GHRP (ghrelin receptor) agonism only
- Combination produces synergistic GH pulse amplification unavailable to monotherapy
- Peak GH Concentration
- 12–15 ng/mL at 30–45 minutes
- 8–10 ng/mL at 20 minutes
- Combination achieves 40–60% higher peak through somatostatin suppression
- Pulse Duration
- 2.5–3 hours sustained elevation
- 90–120 minutes
- Longer pulse duration in combination protocols better mimics nocturnal GH secretion
- IGF-1 Elevation
- 30–50% increase from baseline with 1–2× daily dosing
- 20–35% increase with 2–3× daily dosing
- Combination requires less frequent dosing for equivalent IGF-1 response
- Side Effect Profile
- Transient flushing, water retention in 10–15% of subjects
- Identical side effect incidence and severity
- No additive risk. Combination does not compound side effects
- Dosing Complexity
- Requires simultaneous reconstitution and injection of two peptides
- Single peptide reconstitution and injection
- Monotherapy simplifies logistics but sacrifices pulse synergy